Zura Bio Limited (ZURA) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Sandeep C. Kulkarni.
ZURA tiene fecha de IPO 2023-03-21, 30 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $371.93M.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
